HONG KONG, April 22 /PRNewswire/ -- OrbusNeich's Genous Bio-engineered R stent will be featured at a sponsored symposium during Angioplasty Summit TCT 2008 Asia Pacific.
The symposium, which will take place on April 23 at the Convention
Center of Sheraton Grande Walkerhill Seoul Hotel in Seoul, Korea, includes:
-- "Opening Address" by Seung-Jung Park, the symposium's chairperson, from
12:30 p.m.-12:35 p.m.
-- "Endothelial Progenitor Cell Capture Technology and Beyond" by Michael
Kutryk from 12:35 p.m.-12:50 p.m.
-- "TRIAS HR Pilot Study Long Term Follow-up" by Robbert de Winter of the
Academic Medical Center, Amsterdam, from 12:50 p.m.-1:05 p.m.
-- "HEALING AMI" by Harry Suryapranata from 1:05 p.m.-1:20 p.m.
-- "Q&A Followed by Closing Remarks" by Seung-Jung Park from
1:20 p.m.-1:30 p.m.
"Recent data has highlighted the need for a safer alternative to drug-eluting stents," said Seung-Jung Park. "The data we have seen from both the TRIAS HR Pilot study and the registries underline Genous' superior safety profile with regards to late stage thrombosis."
Unlike drug-eluting stents, Genous, which is coated with an antibody, captures a patient's endothelial progenitor cells (EPCs) to accelerate the natural healing process. EPCs circulate in the bloodstream and are involved in the repair of blood vessels. When attracted to the surface of Genous, EPCs rapidly form an endothelial layer over the stent that provides protection against thrombus and minimizes restenosis.
OrbusNeich designs, develops, manufactures and markets innovative
medical devices for the treatment of vascular diseases. The company's
product portfolio includes the Genous Bio-engineered R stent, an
antibody-coated device that is the first-ever stent to capture a patient's
endothelial progenitor cells (EPCs) to accelerate the natural healing
process following placement. Other products are stents, ballo
Copyright©2008 PR Newswire.
All rights reserved